Costabel, Ulrich
Behr, Jürgen
Crestani, Bruno
Stansen, Wibke
Schlenker-Herceg, Rozsa
Stowasser, Susanne
Raghu, Ganesh
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 26 April 2018
Accepted: 20 August 2018
First Online: 3 September 2018
Ethics approval and consent to participate
: The INPULSIS® trials were conducted in accordance with the principles of the Declaration of Helsinki and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization and were approved by local authorities. The clinical protocol was approved by an independent ethics committee or institutional review board at each participating center. All patients provided written informed consent before study entry.
: Not applicable.
: WS, RSH, and SSt are employees of Boehringer Ingelheim. UC has received grants, personal fees and non-financial support from Boehringer Ingelheim; grants, personal fees and non-financial support from Roche; personal fees from Bayer; and personal fees from GlaxoSmithKline, UCB Celltech, Biogen, FibroGen, and AstraZeneca. JB has received honoraria for lectures and for consulting from Boehringer Ingelheim, Actelion, Bayer and Roche, and is a member of national and international committees for guidelines in IPF and ILD. GR has provided consulting services for Boehringer Ingelheim, Biogen, Bristol-Myers Squibb, Gilead Sciences, FibroGen, Patara, Promedior, Sanofi, and Veracyte and has received research grant support from the National Institutes of Health, Bethesda, MD, USA for studies in IPF.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.